On Thursday, Absci Corp (ABSI) stock saw a decline, ending the day at $3.68 which represents a decrease of $-0.70 or -15.98% from the prior close of $4.38. The stock opened at $4.5 and touched a low ...

On Tuesday, Absci Corp (ABSI) stock saw a modest uptick, ending the day at $4.02 which represents a slight increase of $0.81 or 25.23% from the prior close of $3.21. The stock opened at $3.52 and ...

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report), retaining the price target of ...

Begin your TipRanks Premium journey today. AbSci (ABSI) Company Description: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next ...

Absci Corp (NASDAQ:ABSI) achieved a significant milestone in its collaboration with AstraZeneca by delivering AI-designed antibody sequences within six months. The company announced a new ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...

Operator: Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

On Wednesday, Jones Trading initiated coverage on Absci Corp. (NASDAQ: ABSI), a biotechnology company, with a Buy rating and a price target of $9.00. Currently trading at $2.99, the stock has ...

Charting, Price Performance, News & Related Contracts.

VANCOUVER, Wash. and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for ...